Helse Bergen HF

The Barne og ungdomsklinikken at Helse Bergen HF is conducting studies that aim to improve treatment outcomes for children with serious bacterial and fungal infections.

• Evaluation of antibiotic regimens for chronic wet cough in young children
• Assessment of microbiome changes during infection therapy
• Safety monitoring of novel antifungal agents in pediatric patients

With a growing portfolio of trials, the site leverages its expertise to advance pediatric infectious disease care.

Research at the clinic focuses on preventing and treating heart conditions such as atherosclerotic disease and heart failure, often by testing innovative drug combinations.

• Study of atorvastatin for reducing major cardiovascular events
• Investigation of a novel FXIa inhibitor to prevent recurrent ischemic stroke
• Evaluation of anti‑inflammatory therapy in heart failure with preserved ejection fraction

The program involves more than thirty investigators and contributes to national cardiovascular research goals.

The department is exploring therapies for gastrointestinal cancers and rare tumors, aiming to enhance survival and quality of life.

• Trials in biliary adenocarcinoma and neuroendocrine tumors of the gut
• Adjuvant immunotherapy after resection of high‑risk cutaneous squamous cell carcinoma
• Combination targeted therapy for FGFG3‑altered solid tumors

These studies reflect a commitment to personalized treatment strategies for digestive system malignancies.

Investigations target blood‑related cancers, including various lymphomas and leukemias, to identify more effective and tolerable regimens.

• Evaluation of novel agents in diffuse large B‑cell lymphoma after prior therapy
• Combination of hydroxyurea and valproic acid in acute myeloid leukemia
• Fixed‑duration venetoclax plus obinutuzumab versus continuous ibrutinib in chronic lymphocytic leukemia

The site’s multidisciplinary team supports both adult and pediatric hematology research.

Studies address autoimmune conditions such as atopic dermatitis and multiple sclerosis, testing new biologics and oral agents for disease control.

• Upadacitinib combined with topical steroids for moderate‑to‑severe atopic dermatitis
• Long‑term safety of tolebrutinib in relapsing and progressive multiple sclerosis
• Assessment of a novel anti‑inflammatory antibody in systemic inflammation associated with heart failure

These trials aim to expand therapeutic options for patients with immune‑mediated disorders.

A broad oncology program evaluates cutting‑edge immunotherapies, targeted agents, and combination strategies across many solid tumor types.

• Phase 3 study of pembrolizumab versus placebo after melanoma resection
• Combination of pembrolizumab with VB10.16 in head‑and‑neck squamous cell carcinoma
• Investigation of ziltivekimab in high‑risk locally advanced cutaneous squamous cell carcinoma
• Evaluation of FGFR3‑targeted therapy in advanced dedifferentiated liposarcoma

With 32 active trials, the site contributes significantly to national cancer research efforts.

The clinic conducts research aimed at improving outcomes for neurological disorders such as migraine and multiple sclerosis.

• Atorvastatin trial for episodic migraine prevention
• Long‑term safety assessment of tolebrutinib in multiple sclerosis
• Evaluation of novel oral agents for reducing migraine frequency

These studies seek to offer new therapeutic avenues for patients with nervous system conditions.

Research focuses on obesity and metabolic health, testing lifestyle‑integrated pharmacologic approaches in adolescents.

• Semaglutide combined with blended face‑to‑face and electronic behavioral therapy for adolescent obesity
• Investigation of metabolic biomarkers in patients receiving weight‑loss medication
• Study of dietary interventions alongside pharmacotherapy for BMI reduction

The program highlights a collaborative effort between nutrition specialists and clinical researchers.

Trials address chronic obstructive pulmonary disease and viral infections, aiming to reduce exacerbations and improve viral disease management.

• Tozorakimab added to standard care for reducing severe COPD exacerbations
• Cohort study of mpox virus disease outcomes with antiviral treatment
• Evaluation of inhaled therapies in patients with chronic respiratory symptoms

The site’s respiratory research integrates both pharmacologic and supportive care strategies.

Investigations target dermatologic conditions such as psoriasis and atopic dermatitis, focusing on efficacy and safety of novel topical and systemic agents.

• Phase 2 study of HRO350 oral therapy versus placebo in mild‑to‑moderate psoriasis
• Upadacitinib combined with corticosteroids for severe atopic dermatitis
• Assessment of immune‑modulating antibodies in high‑risk cutaneous squamous cell carcinoma

These efforts aim to broaden therapeutic options for patients with skin‑related diseases.

The clinic evaluates antiviral strategies and vaccine‑adjunct therapies for emerging viral threats and chronic viral infections.

• Clinical outcomes of mpox virus patients treated with tecovirimat
• Safety study of TAF as an add‑on to natalizumab in virus‑related neurological disease
• Investigation of antiviral prophylaxis in high‑risk viral exposure settings

Collaborative work with virology experts supports rapid response to viral health challenges.